United States, Nevada, Las Vegas, DelveInsight’s ‘Dermatomyositis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain.
Key Takeaways from the Dermatomyositis Pipeline Report
Dermatomyositis Overview
Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes of the muscles and skin. Associated symptoms and physical findings may vary widely from case to case as patients may present differently. Muscle abnormalities may begin with aches and weakness of the muscles of the trunk, upper arms, hips, and thighs (proximal muscles). Muscles may be stiff, sore, tender and, eventually, show signs of degeneration (atrophy). Dermatomyositis may be diagnosed based upon a detailed patient history, thorough clinical examination, detection of characteristic physical findings, and certain specialized tests. Glucocorticoids, particularly prednisone, are widely used in treating dermatomyositis and are often used first-line. High dose glucocorticoid therapy may produce adverse side effects, particularly after prolonged use, such as a decrease in bone density, causing bones to become brittle and weakened (osteoporosis); increasing, “superimposed” muscle weakness due to effects of the medication (i.e., corticosteroid myopathy); tissue swelling (edema); peptic ulcers; elevated blood pressure; elevated blood sugar levels; weight gain with fat deposits in the abdomen, face, and/or back of the neck or other findings.
Dermatomyositis Pipeline Analysis: Drug Profile
Lenabasum: Corbus Pharmaceuticals
Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has an acceptable safety and tolerability profiles without evidence of immunosuppression. Lenabasum is currently in phase III stage of development to treat Dermatomyositis.
Discover more about the emerging Dermatomyositis drugs @ Dermatomyositis Treatment Drugs
Dermatomyositis Key Companies
Dermatomyositis Pipeline Therapies
Dermatomyositis Pipeline Therapeutics Assessment
Scope of the Dermatomyositis Pipeline Report
Find out more about the Dermatomyositis treatment options in development @ Dermatomyositis Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies working in the Dermatomyositis Pipeline Segment.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Mumbai (Maharashtra) [India], May 18: AsiaOne successfully orchestrated the 22nd Edition of the Asian Business & Social Forum, a hallmark…
Schneider Electric, the leader in the digital transformation of energy management and automation, has appointed Ruben Llanes as Chief Executive Officer…
practice playing guitars In the bustling world of music, where creativity knows no bounds, musicians are constantly seeking instruments that…
In a world where success stories often seem like a distant dream, Ruchira Darda’s journey stands as a beacon of…
“Products are made in the factory, but brands are created in the mind.” said Walter Landor, Founder of Landor Group.…
Mumbai (Maharashtra) [India], May 18: Phoenixx Artists: Your Gateway to Stardom in Bollywood and Hollywood, Crafted by Gaurang Doshi and…